Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma

por Dimopoulos, M A, Hussein, M, Swern, A S, Weber, D
Publicado 2011

Response to letter, ‘Immortal time bias in retrospective analysis'

por Dimopoulos, M A, Swern, A S, Li, J S, Hussein, M, Weiss, L, Nagarwala, Y, Baz, R
Publicado 2015

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

por Dimopoulos, M A, Swern, A S, Li, J S, Hussein, M, Weiss, L, Nagarwala, Y, Baz, R
Publicado 2014

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

por Barrett-Connor, E., Swern, A. S., Hustad, C. M., Bone, H. G., Liberman, U. A., Papapoulos, S., Wang, H., de Papp, A., Santora, A. C.
Publicado 2011

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)

por Sekeres, M A, Swern, A S, Fenaux, P, Greenberg, P L, Sanz, G F, Bennett, J M, Dreyfus, F, List, A F, Li, J S, Sugrue, M M
Publicado 2014